NEWTON, Mass.--(BUSINESS WIRE)--PGxHealth, a division of Clinical Data, Inc. (NASDAQ: CLDA), today announced that it has established a research collaboration with Deutsches Herzzentrum (DHZ), Munich, Germany, to evaluate the predictive value of genetic markers, including PGxHealth proprietary markers, for response to clopidogrel (Plavix®). Variability in clopidogrel response is a well established phenomenon and several studies have demonstrated that poor response is associated with increased risk of cardiovascular events.1 PGxHealth scientists will collaborate with researchers at DHZ to conduct one of the largest retrospective case/control studies to date to validate genetic variants associated with response to clopidogrel.
